Maurice Pérol, European Society for Medical Oncology (image) European Society for Medical Oncology Share Print E-Mail Caption The findings of the ALEX trial presented by Dr. Pérol at the ELCC (European Lung Cancer Congress) 2018 in Geneva, Switzerland, support the use of alectinib as the new standard of care in the frontline treatment of ALK-positive lung cancer. Alectinib was found to provide longer symptom improvement than crizotinib in ALK-positive non-small-cell lung cancer (NSCLC). Credit © ELCC 2018 Usage Restrictions Picture may only be used with appropriate caption or credit Share Print E-Mail Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.